BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

Group 1 - William Blair initiated coverage on BridgeBio, emphasizing the company's expanding pipeline of treatments for rare genetic conditions [1] - Analyst John Boyle highlighted BridgeBio's unique position with an accelerating launch of Attruby and near-term NDA submissions for disease-modifying therapies, projecting launches in late 2026 to early 2027 [2] - Market surveys indicate that prescribers view Attruby and Amvuttra as superior next-generation products compared to the market leader, Pfizer's Tafamidis, which has annualized sales of approximately $6 billion [3] Group 2 - There is a potential risk from generic entry for BridgeBio in late 2028; however, the threat is considered lower than perceived due to Attruby's strong TTR stabilization and simple dosing regimen, which could support premium pricing [4] - The pivotal PROPEL 3 study data for infigratinib in achondroplasia shows a best-in-class efficacy profile with a favorable once-daily oral formulation, indicating meaningful differentiation in the market [5] - Significant market opportunities are also identified for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), with the CALIBRATE Phase 3 study meeting its primary endpoint in October 2025 [6]